Single nucleotide polymorphisms of multidrug resistance gene 1 (MDR1) and risk of chronic myeloid leukemia
- 223 Downloads
Multidrug resistance gene 1 (MDR1) is known for its involvement in the detoxification through the active transport of toxic compounds from diverse origins outside the cells. These compounds could cause injury to cell DNA, which might lead in cancer like chronic myeloid leukemia (CML). Individual inherited genetic differences related to polymorphism in detoxification enzymes could be an important factor not only in carcinogen metabolism but also in susceptibility of cancer. The present study aimed to investigate the association of three single nucleotide polymorphisms (SNPs) of the MDR1 gene in the susceptibility of CML. We successively have determined the genotype profiles of 1236C>T (exon 12); 2677G>T (exon 21), and 3435C>T (exon 26) SNPs by PCR-RFLP in 89 patients and 99 unrelated healthy controls. Logistic regression was used to assess the effect of each SNP on the development of CML. Interestingly, in exon 12, the 1236TT was significantly associated with the susceptibility of CML when compared to the wild type 1236CC (OR 2.7; 95 % CI 1–7.32, p = 0.041). Additionally, the recessive model 1236TT vs. 1236CC/CT showed a risk of 3.3 fold (p = 0.011) with CML. In exon 26, the 3435CT genotype was associated with a reduced risk of CML (OR 0.5; 95 % CI 0.3–1, p = 0.042). In exon 21, the 2677GT genotype seems to have a protective effect (OR 0.6; 95 % CI 0.32–1.1, p = 0.074). Diplolotypes analysis has demonstrated no effect in susceptibility of CML, but 1236CT/3435CC and 1236CC/2677GT were associated with a protective effect. The haplotypes analysis showed no particular trend (global association p = 0.33). Our findings demonstrate that 1236TT in exon 12 might contribute in the susceptibility of CML, while the 3435CT in exon 26 as well as 1236CT/3435CC and 1236CC/2677GT combinations might be protective factors.
KeywordsMDR1 gene Polymorphism CML
We authors thank the Hassan II Academy of Science and Technology by supporting this study financially.
Conflicts of interest
- 2.Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12623848.PubMedCrossRefGoogle Scholar
- 6.Cojbasic I, Macukanovic-Golubovic L. Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Srp Arh Celok Lek. 2010;138:305–8. Available from: http://www.doiserbia.nb.rs/Article.aspx?ID=0370-81791006305C.PubMedCrossRefGoogle Scholar
- 7.Löffler H, Bergmann J, Hochhaus A, Hehlmann R, Kramer A, and the German CML Study Group. Reduced risk for chronic myelogenous leukemia in individuals with the cytochrome P-450 gene polymorphism CYP1A1*2A. Blood. 2001;98:3874–5. doi: 10.1182/blood.V98.13.3874.
- 11.Lee JS, Ward WO, Liu J, Ren H, Vallanat B, Delker D, et al. Hepatic xenobiotic metabolizing enzyme and transporter gene expression through the life stages of the mouse. PloS one. 2011;6:e24381. Available fromGoogle Scholar
- 17.Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA. 1987;84:265–9. Available fromGoogle Scholar
- 18.Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem. 1989;37:159–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2463300.PubMedCrossRefGoogle Scholar
- 19.Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S. Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. Drug Metab Pharmacokinet. 2004;19:1–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15499164.PubMedCrossRefGoogle Scholar
- 20.Andersen V, Ostergaard M, Christensen J, Overvad K, Tjønneland A, Vogel U. Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009;9:407. doi: 10.1186/1471-2407-9-407.
- 22.Andersen V, Ostergaard M, Christensen J, Overvad K, Tjønneland A, Vogel U. Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009;9:1–11.CrossRefGoogle Scholar
- 23.Jamroziak K, Młynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol. 2004;72:314–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15059065.PubMedCrossRefGoogle Scholar
- 29.Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood. 1998;91:1749–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9473242.PubMedGoogle Scholar
- 30.Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science (New York, NY). 2006;314:1930–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17185601.CrossRefGoogle Scholar
- 33.Hitzl M, Drescher S, van der Kuip H, Schäffeler E, Fischer J, Schwab M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics. 2001;11:293–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11434506.PubMedCrossRefGoogle Scholar
- 34.Vivona D, Bueno CT, Lima LT, Hirata RDC, Hirata MH, Luchessi AD, et al. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells Mol Dis. 2012;48:132–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22134106.PubMedCrossRefGoogle Scholar
- 35.Urayama KY, Wiencke JK, Buffler PA, Chokkalingam AP, Metayer C, Wiemels JL. MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomark Prev. 2007;16:1172–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17548681.CrossRefGoogle Scholar
- 36.Jamroziak K, Balcerczak E, Calka K, Piaskowski S, Urbanska-Rys H, Salagacka A, et al. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res. 2009;33:332–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18639335.PubMedCrossRefGoogle Scholar
- 37.Sailaja K, Surekha D, Rao DN, Raghunadharao D. Association of MDR1 gene polymorphism (G2677T) with chronic myeloid leukemia. Biol Med. 2010;2:17–21.Google Scholar